Hep C Nucleoside Scare: FDA Wants Idenix’s CV Safety Data After BMS Event
This article was originally published in The Pink Sheet Daily
Idenix announced FDA has placed a partial clinical hold on its hepatitis C candidate IDX184 after Bristol-Myers Squibb was forced to halt a study of its similar drug following a serious cardiovascular event. The news sparked new worries concerning a class effect for nucleoside polymerase inhibitors, though Gilead stood by its candidate GS7977’s clean CV profile and Idenix said no CV toxicities have been associated with ‘184.
You may also be interested in...
Bristol and Johnson & Johnson have not abandoned their efforts to take a relevant place in the HCV market, although J&J isn't expected to produce triple combination data until next year.
Gilead issues “Dear Healthcare Provider” letter outlining nine cases of bradycardia in patients who received amiodarone in combination with one of its HCV polymerase inhibitors; FDA has updated labeling for both drugs.
The biotech can move forward with an HCV combo that includes its Phase I nuc and its protease inhibitor now that FDA has partially lifted the hold on the drug.